Suberoylanilide Hydroxamic Acid (SAHA), also known as Vorinostat, is a potent histone deacetylase (HDAC) inhibitor used in both clinical and research settings for epigenetic regulation. It is FDA-approved for the treatment of cutaneous T-cell lymphoma (CTCL) in patients with persistent, recurrent, or progressive disease and can be administered orally. In research, it induces cell cycle arrest, differentiation, and apoptosis in various cancer cell lines, making it a valuable tool in oncology studies. It has been investigated for its potential in treating cancers such as leukemia, breast cancer, and lung cancer due to its ability to reactivate silenced tumor suppressor genes. Additionally, it shows promise in neurodegenerative disease research, including Huntington's and Alzheimer's diseases, by enhancing the expression of neuroprotective genes. Its ability to cross the blood-brain barrier further supports its use in central nervous system disorder studies.